RT Journal Article
SR Electronic
T1 Association of pitavastatin use with bone markers and bone mineral density in postmenopausal women
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.08.14.24312019
DO 10.1101/2024.08.14.24312019
A1 Hyun, Jihye
A1 Sohn, Minji
A1 Oh, Hyeran
A1 Lim, Soo
YR 2024
UL http://medrxiv.org/content/early/2024/08/15/2024.08.14.24312019.abstract
AB BACKGROUND The study aimed to evaluate the effects of pitavastatin therapy on biochemical markers of bone turnover and bone mineral density (BMD) in postmenopausal women with osteopenia or osteoporosis and hypercholesterolemia.METHODS AND RESULTS This prospective observational study recruited 70 postmenopausal Korean women who were administered pitavastatin. Changes in BMD at the femoral neck (FN), total hip (TH), and lumbar spines (LS), as well as laboratory values related to bone turnover markers and lipid profiles, including lipoprotein subfractions, were assessed over 12 months. BMD was further observed during regular clinic visits up to 4 years. A total of 67 patients completed 12 months of pitavastatin therapy. There were no significant changes in BMD (–0.001 ± 0.026 at FN, –0.005 ± 0.032 at TH, and 0.002 ± 0.037 at LS; all Ps > 0.05). Bone markers did not change except for procollagen type 1 N-propeptide (P1NP), which slightly decreased (–4.0 ± 10.3, P < 0.05). Low-density lipoprotein (LDL) cholesterol levels decreased by 36% to 39% from baseline, and the LDL subfraction score decreased from 2.85 ± 1.79 to 1.80 ± 0.63 (P < 0.001). During the extended observation period, BMD at FN and TH decreased by 0.85% and 1.69% per year, respectively, while BMD at the LS was preserved.CONCLUSIONS In postmenopausal women with osteopenia or osteoporosis requiring lipid-lowering therapy, one year of pitavastatin maintained BMD and effectively controlled cholesterol levels. BMD changes during statin therapy were more favorable than the natural decline. These findings suggest pitavastatin can be safely used in menopausal women without compromising bone health.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialTrial registration: NCT06359353Funding StatementThis work was supported, in part, by grants from Seoul National University Bundang Hospital (B-1902-320-004) and JW Pharmaceutical (06-2019-0128).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.Not ApplicableThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Seoul National University Bundang Hospital IRB, Approval Number: B-1902-520-004I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.Not ApplicableI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Not ApplicableI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Not Applicable